Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic ...

Incyte Corporation INCY has entered into a clinical trial collaboration with Denmark-based Genmab A/S GMAB to evaluate a new ...

Genmab (GMAB) and Incyte (INCY) announced a clinical trial collaboration to evaluate a combination of their experimental ...

The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, ...

Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated ...

Patients treated with INCB161734 in combination with mFOLFIRINOX achieved objective response rates (ORR) of 89% and 81% (confirmed + pending), and a disease control rate (DCR) of 100%. Six-month ...

A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

Colorectal cancer can resist KRAS inhibitors in both genetic and non-genetic ways An early inflammation surge within days of treatment helps cancer cells survive Researchers identified the TBK1 ...

Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, ...